| Literature DB >> 33959641 |
Manuel Rattka1, Lina Stuhler1, Claudia Winsauer1, Jens Dreyhaupt2, Kevin Thiessen1, Michael Baumhardt1, Sinisa Markovic1, Wolfgang Rottbauer1, Armin Imhof1.
Abstract
Objective: Since the outbreak of the COVID-19 pandemic, healthcare professionals reported declining numbers of patients admitted with ST-segment myocardial infarction (STEMI) associated with increased in-hospital morbidity and mortality. However, the effect of lockdown on outcomes of STEMI patients admitted during the COVID-19 crisis has not been prospectively evaluated.Entities:
Keywords: COVID-19; Germany; STEMI; epidemiology; lockdown; myocardial infarction; outcome
Year: 2021 PMID: 33959641 PMCID: PMC8093511 DOI: 10.3389/fcvm.2021.638954
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Patient characteristics at baseline.
| Age | 64 ± 13 | 69 ± 12 | 64 ± 14 | 0.1519 |
| Sex (male) | 112 (76) | 12 (75) | 100 (76) | 1.0000 |
| Arterial hypertension | 89 (61) | 11 (69) | 78 (60) | 0.4768 |
| Diabetes | 39 (27) | 3 (19) | 36 (27) | 0.5608 |
| Family history | 35 (24) | 3 (19) | 32 (24) | 0.7627 |
| Smoking | 71 (48) | 8 (50) | 63 (48) | 0.8853 |
| Obesity | 21 (14) | 2 (13) | 19 (15) | 1.0000 |
| TIA/stroke | 8 (5) | 2 (13) | 6 (5) | 0.2109 |
| OSAS | 7 (5) | 1 (6) | 6 (5) | 0.5616 |
| COPD | 2 (3) | 1 (6) | 4 (3) | 0.4427 |
| CKD | 35 (24) | 5 (31) | 30 (23) | 0.5345 |
| FCV-19S questionnaire (score) | 14 (9, 17) | 12 (9, 17) | 14 (9, 17) | 0.8976 |
| CSS questionnaire (score) | 38 (25, 70) | 31 (13, 50] | 39 (27, 71) | 0.2018 |
TIA, transient ischemic attack; OSAS, obstructive sleep apnea syndrome; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; FCV-19S, Fear of COVID-19 Scale; CSS, COVID-19 Stress Scales.
two-sample t-test.
Wilcoxon rank sum test.
Fisher's exact test.
chi.
Clinical characteristics at baseline.
| I | 34 (27) | 1 (8) | 33 (29) | |
| II | 25 (20) | 0 (0) | 25 (22) | |
| III | 10 (8) | 3 (23) | 7 (6) | |
| IV | 57 (45) | 9 (69) | 48 (42) | |
| Yes | 50 (38) | 11 (85) | 39 (33) | |
| No | 83 (62) | 2 (15) | 81 (68) | |
| Immediately | 60 (45) | 2 (15) | 58 (49) | |
| ≤ 3 h | 27 (20) | 2 (15) | 25 (21) | |
| ≤ 12 h | 14 (11) | 3 (23) | 11 (9) | |
| ≤ 24 h | 12 (9) | 0 (0) | 12 (10) | |
| > 24 h | 19 (14) | 6 (46) | 13 (11) | |
| Time to FMC (hours) | 2.0 (0.3, 24.0) | 11.0 (2.0, 144.0) | 2.0 (0.3, 16.0) | |
| Systolic bp (mmHg) | 117 ± 28 | 116 ± 29 | 117 ± 29 | 0.9009 |
| Diastolic bp (mmHg) | 67 ± 20 | 76 ± 19 | 65 ± 19 | 0.0579 |
| Troponin T (ng/L) | 318 (63, 1,301) | 746 (292, 3,899) | 244 (53, 1,124) | |
| NT-pro BNP (pg/ml) | 354 (91, 1,879) | 1,120 (237, 6,459) | 331 (83, 1,712) | 0.0717 |
| Creatinine (μmol/L) | 84 (71, 110) | 86 (74, 115) | 84 (71, 109) | 0.6503 |
| Normal | 4 (3) | 0 (0) | 4 (3) | 0.2620 |
| Mildly reduced | 31 (23) | 4 (27) | 27 (22) | |
| Moderately reduced | 55 (40) | 3 (20) | 52 (43) | |
| Severely reduced | 46 (34) | 8 (53) | 38 (31) | |
| LVEDP (mmHg) | 26 (17, 32) | 34 (27, 36) | 24 (17, 29) | |
| Door-to-needle-time (min) | 54 (28, 80) | 83 (59, 117) | 46 (28, 74) | |
| LAD | 67 (49) | 11 (79) | 56 (46) | 0.0815 |
| LCX | 19 (14) | 1 (7) | 18 (15) | |
| RCA | 51 (37) | 2 (14) | 49 (40) | |
| Yes | 27 (20) | 9 (56) | 18 (15) | |
| No | 111 (80) | 7 (44) | 104 (85) | |
| Time at hospital (days) | 4 (3, 6) | 5 (2, 6) | 4 (3, 6) | 0.9445 |
FMC, first medical contact; BNP, brain natriuretic peptide; bp, blood pressure; LVED, left ventricular end diastolic pressure; LAD, left anterior descending; LCX, left circumflex artery; RCA, right coronary artery.
two-sample t-test.
Wilcoxon rank sum test.
Fisher's exact test.
.
Boldface denotes significance of p-values.
Figure 1Kaplan Meier plot showing survival of STEMI patients admitted during (lockdown group), and outside of COVID-19 associated lockdown (pre-/post-lockdown group).
Patient characteristics at follow up.
| I | 46 (45) | 5 (50) | 41 (44) | 0.1367 |
| II | 35 (34) | 1 (10) | 34 (37) | |
| III | 9 (9) | 1 (10) | 8 (9) | |
| IV | 13 (13) | 3 (30) | 10 (11) | |
| LVEF | 53 (45, 60) | 47 (35, 63) | 53 (45, 60) | 0.4327 |
| Troponin T (ng/L) | 19 (10, 39) | 26 (19, 81) | 17 (10, 33) | 0.1300 |
| NT-pro BNP (pg/ml) | 483 (187, 1,092) | 1,014 (187, 3,559) | 483 (195, 964) | 0.4976 |
| Creatinine (μmol/L) | 81 (74, 93) | 83 (74, 131) | 80 (74, 93) | 0.5377 |
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide.
Wilcoxon rank sum test.
Fisher's exact test.
Identification of predictors of intentionally delayed presentation.
| Age | 0.965 | 0.924–1.008 | 0.1133 |
| Sex (female) | 2.187 | 0.567–8.437 | 0.2558 |
| Admission during lockdown | 16.393 | 1.692–166.67 | |
| FCV-19S questionnaire (score) | 1.083 | 0.939–1.249 | 0.2760 |
| CSS questionnaire (score) | 0.986 | 0.952–1.021 | 0.4280 |
FCV-19S, Fear of COVID-19 Scale; CSS, COVID-19 Stress Scales. Boldface denotes significance of p-values.